Larvol Delta - Anixa-Biosciences-Announces-Positive-Phase-1-Data-for-Investigational-Breast-Cancer-Vaccine-Primary-Endpoints-Were-Met-and-Immune-Response-Observed-in-74-of-Participants

alpha-lactalbumin vaccine - Anixa Biosci, Cleveland Clinic

https://www.prnewswire.com/news-releases/anixa-biosciences-announces-positive-phase-1-data-for-investigational-breast-cancer-vaccine-primary-endpoints-were-met-and-immune-response-observed-in-74-of-participants-302639634.html

Dec 11, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next